Adverse events were reported by @ ( @ % ) of @ patients receiving roflumilast and by @ ( @ % ) of @ patients in the placebo group ; adverse event-associated patient withdrawal from the study was also more common in the roflumilast group ( @/@ -LSB- @ % -RSB- ) than in the placebo group ( @/@ -LSB- @ % -RSB- ) .